TP53 and colorectal carcinoma: One group [31] compared RAS, BRAF, PIK3CA, and TP53 status between 84 pairs of primary CRC and liver metastases and found a concordant rate of 97.6%, 98.8%, and 92.8% for RAS/BRAF, PIK3CA, and TP53, respectively.